Home

TRAIL-R4 (human)

Overview TRAIL-R4 Receptor for the cytotoxic ligand TRAIL. Contains a truncated death domain and hence is not capable of inducing apoptosis but protects against TRAIL-mediated apoptosis. Reports are contradictory with regards to its ability to induce the NF- kappa-B pathway. According to PubMed:9382840, it cannot but according to PubMed:9430226, it can induce the NF-kappa-B pathway. Widely expressed, in particular in fetal kidney, lung and liver, and in adult testis and liver. Also expressed in peripheral blood leukocytes, colon and small intestine, ovary, prostate, thymus, spleen, pancreas, kidney, lung, placenta and heart. Note: This description may include information from UniProtKB. Protein type: Membrane protein, integral Cellular Component: integral to membrane Molecular Function: transmembrane receptor activity; TRAIL binding Biological Process: apoptosis; signal transduction; negative regulation of apoptosis Reference #:  Q9UBN6 (UniProtKB) Alt. Names/Synonyms: CD264; DCR2; Decoy receptor 2; decoy with truncated death domain; TNF receptor-related receptor for TRAIL; TNF-related apoptosis-inducing ligand receptor 4; TNFRSF10D; TR10D; TRAIL receptor 4; TRAIL receptor with a truncated death domain; TRAIL-R4; TRAILR4; TRUNDD; Tumor necrosis factor receptor superfamily member 10D; tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain Gene Symbols: TNFRSF10D Molecular weight: 41,823 Da Basal Isoelectric point: 6.19  Predict pI for various phosphorylation states Protein-Specific Antibodies or siRNAs from Cell Signaling Technology®

Select Structure to View Below TRAIL-R4

STRING  |  Scansite  |  Phospho.ELM  |  Pfam  |  DISEASE  |  Source  |  InnateDB  |  UCSD-Nature  |  GeneCards  |  UniProtKB  |  Entrez-Gene  |  GenPept  |  Ensembl Gene

	Modification Sites and Domains	Show Modification Legend
Click here to view phosphorylation modifications only

	Modification Sites in Parent Protein, Orthologs, and Isoforms	Show Modification Legend

SS  SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.	MS  MS: The number of records in which this modification site was assigned using ONLY proteomic discovery-mode mass spectrometry.			human
0	1		T134-p	NKSSCTTtRDTVCQC
0	1		S238-p	SCRKKFIsyLkGICs
0	1		Y239-p	CRKKFIsyLkGICsG
0	1		K241-u	KKFIsyLkGICsGGG
0	1		S245-p	syLkGICsGGGGGPE
0	2		Y284-p	NETLSNRyLQPTQVS
0	2		Y374-p	VGSEKLFyEEDEAGS

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E Produced by 3rd Millennium  |  Design by Digizyme ©2003-2013 Cell Signaling Technology, Inc.